PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration

Vaccine

Volumn 29, Issue 4, 2011, Pages 804-812

  Stano, Armando ^a   van der Vlies, André J ^a   Martino, Mikael M ^a   Swartz, Melody A ^a   Hubbell, Jeffrey A ^a   Simeoni, Eleonora ^a  

^a EPFL   (Switzerland)

Author keywords

Cytotoxic T lymphocytes; Flagellin; Mucosal vaccine; Nanoparticles

Indexed keywords

CYTOKINE; FLAGELLIN; NANOPARTICLE; OVALBUMIN; POLYMER; POLYPROPYLENE SULFIDE; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES; ANTIGEN-PRESENTING CELLS; DRUG CARRIERS; FEMALE; HUMANS; IMMUNITY, MUCOSAL; LUNG; MICE; MICE, INBRED C57BL; NANOPARTICLES; NASAL MUCOSA; OVALBUMIN; POLYPROPYLENES; RECTUM; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VACCINATION; VAGINA;

EID: 78650546875     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.010     Document Type: Article

References (35)

1. Plotkin S.A. Vaccines: past, present and future. Nat Med 2005, 11(4):S5-S11.
2. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(2):148-158.
3. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J Immunol 2009, 183(11):6883-6892.
4. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(4):S45-S53.
5. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005, 5(12):905-916.
6. Eriksson K., Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 2002, 14(5):666-672.
7. Sharma S., Mukkur T.K.S., Benson H.A.E., Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 2009, 98(3):812-843.
8. Hubbell J.A., Thomas S.N., Swartz M.A. Materials engineering for immunomodulation. Nature 2009, 462(7272):449-460.
9. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26(13):1626-1637.
10. Vajdy M., Srivastava I., Polo J., Donnelly J., O'Hagan D., Singh M. Mucosal adjuvants and delivery systems for protein-DNA- and RNA-based vaccines. Immunol Cell Biol 2004, 82(6):617-627.
11. Rehor A., Hubbell J.A., Tirelli N. Oxidation-sensitive polymeric nanoparticles. Langmuir 2005, 21(1):411-417.
12. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Controlled Release 2006, 112(1):26-34.
13. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neill C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
14. van der Vlies A.J., O'Neil C.P., Hasegawa U., Hammond N., Hubbell J.A. Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. Bioconjug Chem 2010, 21(4):653-662.
15. Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA, Swartz MA. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. doi:10.1016/j.vaccine.2010.09.077.
16. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82(1):70-77.
17. Heritage P.L., Underdown B.J., Arsenault A.L., Snider D.P., McDermott M.R. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am J Respir Crit Care Med 1997, 156(4):1256-1262.
18. Udenfriend S., Stein S., Bohlen P., Dairman W., Leimgruber W., Weigele M., et al. A Reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 1972, 178(4063):871-872.
19. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?. J Pharm Sci 2007, 96(3):473-483.
20. Tobio M., Gref R., Sanchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998, 15(2):270-275.
21. Vila A., Gill H., McCallion O., Alonso M.J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Controlled Release 2004, 98(2):231-244.
22. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "Slip" through the human mucus barrier. Angew Chem Int Ed Engl 2008, 47(50):9726-9729.
23. McDermott P.F., Ciacci-Woolwine F., Snipes J.A., Mizel S.B. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 2000, 68(10):5525-5529.
24. Mizel S.B., West A.P., Hantgan R.R. Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. J Biol Chem 2003, 278(26):23624-23629.
25. Bates J.T., Uematsu S., Akira S., Mizel S.B. Direct stimulation of tlr5(+/+) CD11c(+) cells is necessary for the adjuvant activity of Flagellin. J Immunol 2009, 182(12):7539-7547.
26. Lind E.F., Ahonen C.L., Wasiuk A., Kosaka Y., Becher B., Bennett K.A., et al. Dendritic cells require the NF-kappa B2 pathway for cross-presentation of soluble antigens. J Immunol 2008, 181(1):354-363.
27. Yoshimura S., Bondeson J., Foxwell B.M.J., Brennan F.M., Feldmann M. Effective antigen presentation by dendritic cells is NF-kappa B dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001, 13(5):675-683.
28. Braga C.J.M., Massis L.M., Sbrogio-Almeida M.E., Alencar B.C.G., Bargieri D.Y., Boscardin S.B., et al. CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 2010, 28(5):1373-1382.
29. Cunningham A.F., Khan M., Ball J., Toellner K.M., Serre K., Mohr E., et al. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 2004, 34(11):2986-2995.
30. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25(4):763-775.
31. Le Moigne V., Robreau G., Mahana W. Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen. Mol Immunol 2008, 45(9):2499-2507.
32. Bargieri D.Y., Rosa D.S., Braga C.J.M., Carvalho B.O., Costa F.T.M., Espindola N.M., et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 2008, 26(48):6132-6142.
33. Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006, 74(2):1113-1120.
34. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006, 74(1):694-702.
35. Salman H.H., Irache J.M., Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 2009, 27(35):4784-4790.